A Prospective Observational Study of Mycophenolate Mofetil Treatment in Progressive Diffuse Cutaneous Systemic Sclerosis of Recent Onset
The Journal of Rheumatology,

Mendoza FA et al. – Patients with diffuse progressive cutaneous systemic sclerosis (SSc) of recent onset treated with mycophenolate mofetil (MMF) experienced marked improvement in skin involvement and stabilization of pulmonary function. Skin biopsies from 3 patients demonstrated histopathological improvement and decreased expression of fibrosis–related genes.

Methods
  • Twenty–five previously untreated consecutive patients with recent–onset (< 24 mo) diffuse progressive cutaneous SSc received MMF as the only disease–modifying therapy.
  • Modified Rodnan skin score (mRSS) and affected body surface area (BSA) were compared from initiation of MMF to study end.
  • Pulmonary function tests performed at the same institution before therapy and at study end were available in 15 patients.
  • Histopathology and real–time PCR assessment of fibrosis–related gene expression were performed before and after treatment in skin biopsies from 3 patients.

Results
  • At 18.2 ± 8.73 months of MMF therapy (median 2000 mg/day) the mRSS decreased from 24.56 ± 8.62 to 14.52 ± 10.9 (p = 0.0004) and the affected BSA from 36% ± 16% to 14% ± 13.3% (p = 0.00001).
  • Pulmonary function tests remained stable from initiation of MMF to the end of the study.
  • Skin histopathology showed a remarkable reduction in accumulation of fibrotic tissue.
  • Realtime PCR of skin biopsies demonstrated a marked decrease in expression of fibrosis–related genes.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Rheumatology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Rheumatology Articles

1 Could ibuprofen be an anti-aging medicine? Buck Institute for Research on Aging News, December 22, 2014

2 Rituximab for the treatment of relapses in ANCA-associated vasculitis Arthritis & Rheumatism, August 1, 2014    Clinical Article

3 Mayo Clinic researchers: TNF inhibitors may increase cancer risk in the eye Mayo Clinic, November 19, 2014

4 Ten common mistakes in the management of lupus nephritis American Journal of Kidney Diseases, January 3, 2014    Clinical Article

5 Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: A meta-analysis Clinical Infectious Diseases, April 28, 2014    Evidence Based Medicine

6 Fish consumption and risk of rheumatoid arthritis: A dose-response meta-analysis Arthritis Research & Therapy, October 8, 2014    Evidence Based Medicine    Review Article

7 Identification of lymphoma predictors in patients with primary Sjögren's syndrome: A systematic literature review and meta-analysis Rheumatology International, June 5, 2014    Evidence Based Medicine    Review Article

8 Methotrexate and lung disease in rheumatoid arthritis – A meta-analysis of randomized controlled trials Arthritis & Rheumatism, December 27, 2013    Evidence Based Medicine    Review Article    Clinical Article

9 Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: A clinical observational study Rheumatology, February 11, 2014    Clinical Article

10 The association of serum anti-ribosomal P antibody with clinical and serological disorders in systemic lupus erythematosus: A systematic review and meta-analysis Lupus, November 26, 2014    Evidence Based Medicine    Review Article

11 Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: A multicentre, randomised, double-blind, non-inferiority trial versus celecoxib Annals of Rheumatic Diseases, January 23, 2015    Clinical Article

12 Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis Joint, Bone, Spine, July 3, 2014    Clinical Article

13 The comparative safety of TNF inhibitors in rheumatoid arthritis - a meta-analysis update of 44 randomized controlled trials American Journal of Medicine, October 6, 2014    Clinical Article

14 Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients Seminars in Arthritis and Rheumatism, January 5, 2015    Clinical Article

15 Intra articular injection with corticosteroids in patients with recent onset rheumatoid arthritis: subanalyses from the BeSt study Clinical Rheumatology, February 17, 2014    Clinical Article

16 A combination of celecoxib and famciclovir is efficacious in the treatment of fibromyalgia: Results of a phase IIa randomized, double-blind, placebo-controlled study American College of Rheumatology News, December 2, 2014    Clinical Article

17 Risk of malignancy in patients with giant cell arteritis and polymyalgia rheumatica: A systematic review and meta-analysis Seminars in Arthritis and Rheumatism, June 27, 2014    Evidence Based Medicine    Review Article

18 Coffee or tea consumption and the risk of rheumatoid arthritis: A meta-analysis Clinical Rheumatology, October 15, 2014    Clinical Article

19 Denosumab and osteonecrosis of the jaws: The pharmacology, pathogenesis and a report of two cases Australian Dental Journal, August 25, 2014

20 Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: A systematic review and meta-analysis Annals of Rheumatic Diseases, January 7, 2015    Evidence Based Medicine    Review Article

Indexed Journals in Rheumatology: Arthritis & Rheumatism, Annals of Rheumatic Diseases, Journal of Rheumatologymore

Looking for a physician job? Let us help!

Register now for our free job placement service.
A career consultant will contact you soon.
Click Here for more information.

Get Started Now!

Free-of-charge, no obligation.

Terms and Conditions For M3 Career Consult

By registering with the M3 Career Consult service you authorize M3 USA Corporation to represent you in your job search. The following is a summary of the terms of our service and our mutual obligations to help you find a job:

  • You designate M3 to act as your agent and represent you in your job search;
  • You will not pay us for this service
  • You will advise us of any companies or positions to which you apply or have applied;
  • You will advise us if you believe you are not capable of performing a position for which we submit you, or for which you interview;
  • You will keep all information we provide you about companies or positions strictly confidential;
  • You will promptly provide us with information we request of you;
  • You will make yourself reasonably available for phone, video and in-person conversations and interviews;
  • You will be truthful in all of your communications with us; and
  • You will advise us if anything above changes.
 

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List